Argus upgraded AbbVie (ABBV) to Buy from Hold.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABBV:
- Is AbbVie (NYSE:ABBV) Stock a Buy After Its Dividend Hike?
- AbbVie price target raised to $200 from $195 at UBS
- AbbVie, EvolveImmune Therapeutics announce collaboration
- AbbVie, EvolveImmune announce collaboration, option-to-license agreement
- AbbVie price target raised to $240 from $200 at Cantor Fitzgerald